Expert: Combination of three fully human IgG1 monoclonal antibodies (atoltivimab + maftivimab + odesivimab) targeting non-overlapping epitopes on Ebola virus glycoprotein (GP). Blocks viral entry and promotes Fc-mediated clearance.

Everyday: A cocktail of three antibodies that all grab onto different parts of the Ebola virus surface protein, blocking the virus from entering human cells. Like putting three different locks on the door the virus uses to get in.

Targets: ["EBOV GP"]

Primary EP: [{"id":"palm-mortality","name":"28-day mortality","type":"PRIMARY","unit":"%","results":[{"notes":"33.5% 28-day mortality (58/174)","value":33.5,"arm_id":"regn-eb3-palm","arm_name":"REGN-EB3 (Inmazeb)

Efficacy: PALM showed REGN-EB3 (33.5% mortality) and MAb114 (35.1%) were superior to ZMapp (51.3%) and remdesivir (53.1%). The DSMB stopped enrollment early due to clear superiority. In low viral load patients, REGN-EB3 mortality was only 9.9% vs 33% ZMapp.

Safety: PALM (n=681, Ebola outbreak): Safety assessment limited by severe underlying disease. Hypotension 3%, fever 7% with REGN-EB3. AEs difficult to distinguish from Ebola disease course. Single-infusion RE

First FDA-approved treatment for Ebola (Zaire ebolavirus). Revenue is lumpy — dependent on government stockpile contracts and outbreak response. PALM trial: 94% survival vs 49% with ZMapp. Not a commercial growth driver but important public health contribution.

{"keyRisks":[{"category":"Hypersensitivity/Infusion reactions","description":"Fever, chills, tachycardia, tachypnea, vomiting. May be difficult to distinguish from Ebola symptoms. Slow or stop infusion.","incidenceRate":"7-18%"},{"category":"Hypotension","description":"During infusion. May require IV fluids and vasopressors in critically ill Ebola patients.","incidenceRate":"Common in critically ill patients"}],"monitoring":["Vital signs during and after infusion","Distinguish infusion reactions from Ebola disease progression"],"classWarnings":["Monoclonal antibody cocktail targeting Ebola glycoprotein","Safety data from PALM trial during active Ebola outbreak — confounded by underlying disease"],"hasBoxedWarning":false}